Healthcare associated infections (HAIs)


One of the biggest patient safety challenges of our time is healthcare associated infections (HAIs). 

Every year in the EU, it is estimated that 4.1 million people are affected by HAIs. This results in 37,000 deaths and adds estimated costs of over €6 billion, according to the European Centre for Disease Prevention and Control (ECDC).

In vitro diagnostics (IVDs) can accurately diagnose patients with drug-resistant infections so that they can be appropriately managed. Healthcare institutions can also use this diagnostic information to reduce the risk of other patients being infected.

For example, staff can follow specific infection-control protocols when caring for the infectious patient and take steps to limit contact between patients. Protective clothing and adequate sterilization of surgical devices are also essential to good hygiene and patient safety.

 

Position paper

Position paper - healthcare-associated infections (HCAIs)

Healthcare-associated infections (HCAIs) are infections caused by a wide variety of bacteria, fungi, and viruses during the course of receiving medical care. They are a major contributor to morbidity and mortality, affecting at least 4,100,000 patients and causing 37,000 deaths every year in Europe. Moreover, HCAIs place a significant burden on European healthcare systems by causing 16 million additional days of hospitalisation every year and undermining the results of expensive medical treatments (annual financial losses in Europe are estimated at approximately €7 billion, including direct costs only).

In vitro diagnostics (IVDs) play an important role in reducing HCAI-related risks and complications for patients. EDMA calls for clear best practice guidelines on the prevention of HCAIs to ensure a high level of patient safety all across Europe.